Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CLNN

Clene Inc

Feb 06 • 04:00PM ET

4.29

+0.37 9.44 %

Healthcare • Biotechnology • USA • NASD

Peers: CYCN IMNM KNSA MTEM NAII PAVM RARE TERN XAIR

| Held by: VTI VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.39	Insider Own	26.48%	Shs Outstand	10.22M	Perf Week	4.89%
Market Cap	50.53M	Forward P/E	-	EPS next Y	-2.06	Insider Trans	-13.70%	Shs Float	8.66M	Perf Month	-31.69%
Enterprise Value	63.92M	PEG	-	EPS next Q	-0.55	Inst Own	6.84%	Short Float	8.69%	Perf Quarter	-60.20%
Income	-30.50M	P/S	240.62	EPS this Y	58.98%	Inst Trans	14.11%	Short Ratio	4.35	Perf Half Y	16.89%
Sales	0.21M	P/B	-	EPS next Y	11.46%	ROA	-113.20%	Short Interest	0.75M	Perf YTD	-26.92%
Book/sh	-1.21	P/C	6.38	EPS next 5Y	65.56%	ROE	-1738.36%	52W High	13.50 -68.22%	Perf Year	-7.34%
Cash/sh	0.67	P/FCF	-	EPS past 3/5Y	-21.43% 21.17%	ROIC	-441.20%	52W Low	2.28 88.15%	Perf 3Y	-86.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-22.08% -	Gross Margin	-637.38%	Volatility	9.85% 11.00%	Perf 5Y	-96.73%
Dividend TTM	-	EV/Sales	304.38	EPS Y/Y TTM	23.37%	Oper. Margin	-11328.50%	ATR (14)	0.51	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.52	Sales Y/Y TTM	-49.17%	Profit Margin	-14250.47%	RSI (14)	38.48	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.53	EPS Q/Q	-1301.31%	SMA20	-11.13%	Beta	0.68	Target Price	31.86
Payout	-	Debt/Eq	-	Sales Q/Q	-82.76%	SMA50	-28.95%	Rel Volume	0.43	Prev Close	3.92
Employees	76	LT Debt/Eq	-	Earnings	Nov 13 BMO	SMA200	-23.39%	Avg Volume	172.91K	Price	4.29
IPO	Aug 27, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	-46.50% -76.67%	Trades		Volume	74,724	Change	9.44%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Downgrade	Oppenheimer	Outperform → Perform
Jul-18-22	Initiated	H.C. Wainwright	Buy	$16
May-02-22	Initiated	Canaccord Genuity	Buy	$10
Sep-28-21	Initiated	Oppenheimer	Outperform	$20

Jan-23-26 01:02AM	Clene Conference: FDA Grants Type C Meeting as CLNN Eyes ALS CNM-Au8 Accelerated Approval in Q2 (MarketBeat)
Jan-16-26 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jan-12-26 08:30AM	Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting (GlobeNewswire) -19.00%
Jan-09-26 08:30AM	Clene Announces Registered Direct Offering of Over $28 Million (GlobeNewswire) +7.12%
Dec-09-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire) +6.31%
08:00AM	Loading…
Dec-03-25 08:00AM	Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8 (GlobeNewswire) -22.03%
Dec-02-25 05:39PM	Clene to Provide CNM-Au8 ALS Program Update (GlobeNewswire)
Nov-20-25 08:00AM	Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference (GlobeNewswire)
Nov-13-25 09:00AM	Clene Inc. (CLNN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -22.42%
08:00AM	Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
Nov-10-25 05:15PM	Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -5.35%
Nov-06-25 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -14.19%
Oct-20-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Oct-15-25 08:30AM	Clene to Participate in a Panel Discussion at the Maxim Growth Summit (GlobeNewswire)
Sep-25-25 08:00AM	Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8 Improves Brain Energy Metabolism in Multiple Sclerosis Patients (GlobeNewswire)
08:30AM	Loading…
Sep-04-25 08:30AM	Clene Presents Preclinical Data Supporting CNM-Au8 for the Treatment of Parkinson's Disease (GlobeNewswire) +6.44%
Sep-02-25 08:00AM	Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire) +20.11%
Aug-14-25 09:15AM	Clene Inc. (CLNN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
09:10AM	MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
08:38AM	Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
Aug-13-25 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Aug-12-25 05:20PM	Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-05-25 08:30AM	Clene to Present at the Canaccord 45th Annual Growth Conference (GlobeNewswire)
Aug-04-25 05:20PM	Castle Biosciences, Inc. (CSTL) Q2 Earnings and Revenues Surpass Estimates (Zacks) +7.16%
Jul-16-25 07:00AM	Presenting on Emerging Growth Conference 84 Day 2 on July 17; Register to live stream (GlobeNewswire)
Jun-30-25 08:00AM	Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings (GlobeNewswire)
Jun-09-25 09:00AM	Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025 (ACCESSWIRE)
May-20-25 07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire)
May-07-25 09:15AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -10.53%
08:00AM	Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights (GlobeNewswire)
08:00AM	Loading…
08:00AM	Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference (Newsfile)
May-05-25 05:45PM	Certara, Inc. (CERT) Q1 Earnings and Revenues Beat Estimates (Zacks)
Apr-16-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream (GlobeNewswire)
Apr-15-25 07:00AM	Presenting on Emerging Growth Conference 81 Day 1 on April 16; Register to live stream (GlobeNewswire)
Apr-14-25 08:30AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Apr-08-25 08:00AM	Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8 Treatment At the American Academy of Neurology Late-Breaking Science Session (GlobeNewswire) +7.52%
Apr-01-25 08:30AM	Clene to Present at the Jones Healthcare and Technology Innovation Conference (GlobeNewswire) -16.23%
Mar-25-25 08:30AM	Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025 (NewMediaWire) -11.73%
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -5.31%
08:00AM	Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
Mar-18-25 03:30PM	Q1 Virtual Investor Summit: On-Demand Presentations Now Live (ACCESS Newswire)
Mar-12-25 08:00AM	Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 Treatment (GlobeNewswire)
Mar-06-25 08:30AM	Clene to Present at the 37TH Annual Roth Conference (GlobeNewswire)
Feb-27-25 09:15AM	Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11 (ACCESSWIRE)
Feb-25-25 08:00AM	Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8 's Impact on NfL Reduction (GlobeNewswire)
Feb-14-25 11:29AM	Is Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In? (Insider Monkey) +5.48%
Jan-13-25 11:18AM	IBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALS (NewMediaWire)
Dec-30-24 09:20AM	IBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R) (NewMediaWire)
Dec-19-24 02:44PM	IBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease Treatments (NewMediaWire)
08:00AM	Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan (GlobeNewswire)
Dec-11-24 11:15AM	IBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval Pathway (NewMediaWire)
Dec-10-24 08:30AM	FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8 Biomarker Data in ALS (GlobeNewswire)
Nov-15-24 07:11AM	Clene price target lowered to $83 from $86 at Canaccord (TipRanks)
Nov-13-24 08:00AM	Clene Reports Third Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -9.06%
Oct-25-24 12:09PM	IBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA Leadership (NewMediaWire)
Oct-21-24 01:13PM	IBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor Conferences (NewMediaWire)
Oct-11-24 02:55PM	IBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private Placements (NewMediaWire)
Oct-09-24 01:31PM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Participation at Two Upcoming Investor Conferences (NewMediaWire) +14.04%
08:00AM	Clene to Present at Upcoming October Conferences (GlobeNewswire)
Oct-03-24 10:46AM	IBN Coverage: Clene (NASDAQ: CLNN) Closes on Direct Offering, Concurrent Private Placements Totaling $7.3M (NewMediaWire)
Oct-02-24 07:21AM	IBN Coverage: Clene (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements (NewMediaWire) +6.30%
Oct-01-24 04:00PM	Clene Announces Closing of $7.3 Million Registered Direct Offering and Concurrent Private Placements and Amendment of Debt Facility (GlobeNewswire)
Sep-30-24 08:30AM	Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules (GlobeNewswire)
Sep-26-24 11:44AM	IBN Coverage: Clene (NASDAQ: CLNN) to Discuss CNM-Au8(R) Data FDA Leadership (NewMediaWire)
Sep-16-24 08:30AM	Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data (GlobeNewswire) -17.06%
Sep-04-24 11:27AM	IBN Coverage: Clene (NASDAQ: CLNN) Management to Present at H.C. Wainwright Investment Conference (NewMediaWire) +12.50%
Sep-03-24 10:38AM	IBN Coverage: Clene (NASDAQ: CLNN) Positioned as Leader in Addressing Neurodegenerative Diseases (NewMediaWire) +12.33%
08:00AM	Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-29-24 12:13PM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Discusses CNM-Au8(R) Trial Results on BioMedWire Podcast (NewMediaWire)
Aug-23-24 10:17AM	IBN Coverage: Clene's (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers, Long-term Survival in ALS Trials (NewMediaWire)
Aug-13-24 12:47PM	IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions (NewMediaWire)
Aug-12-24 08:00AM	IBN Coverage: Clene (NASDAQ: CLNN) CEO Spotlighted in Recent BioMedWire Podcast Episode (NewMediaWire)
Aug-09-24 09:00AM	IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates (NewMediaWire) +14.74%
Aug-08-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc. (GlobeNewswire)
Aug-07-24 08:23AM	Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire) -23.47%
Aug-06-24 08:00AM	Clene Announces New CNM-Au8 Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS (GlobeNewswire) +47.00%
Aug-05-24 08:00AM	Clene to Present at the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire) -7.62%
Jul-17-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 2 on July 18 Register Now (GlobeNewswire)
Jul-16-24 07:00AM	Presenting on the Emerging Growth Conference 73 Day 1 on July 17 Register Now (GlobeNewswire)
Jul-12-24 10:34AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
Jul-11-24 09:00AM	Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS (GlobeNewswire) -9.61%
Jul-09-24 08:00AM	Clene Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -21.54%
Jun-24-24 08:00AM	Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire)
Jun-21-24 07:09AM	Clene Presents Preliminary Data for CNM-Au8 as a Potential Treatment for Rett Syndrome (GlobeNewswire)
Jun-18-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:00AM	Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting (GlobeNewswire)
Jun-12-24 07:46AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-05-24 08:00AM	Clene to Present at the Emerging Growth Conference (GlobeNewswire)
May-28-24 07:30AM	Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8 in ALS (ACT-EAP) (GlobeNewswire)
May-14-24 08:00AM	Clene to Present at Upcoming May Conferences (GlobeNewswire)
May-10-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-08-24 12:54PM	CLNN Stock Earnings: Clene Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:55AM	Clene Inc. (CLNN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights (GlobeNewswire)
06:00AM	3 Speculative Penny Stocks Offering High-Upside Potential for Under a Buck (InvestorPlace)
May-01-24 08:30AM	IBN Announces From Lab to Launch Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)
Apr-16-24 04:01PM	Evidence for Clene's CNM-Au8 as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting (GlobeNewswire) -6.46% +9.55%
Mar-19-24 08:30AM	IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington (GlobeNewswire)

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ugwumba Chidozie	10% Owner	Feb 03 '26	Sale	4.10	5,559	22,792	550,000	Feb 05 10:18 AM
Symbiosis II LLC	Prior board member	Jan 29 '26	Proposed Sale	4.37	60,842	265,731		Feb 03 03:36 PM
Ugwumba Chidozie	10% Owner	Jan 29 '26	Sale	4.32	15,284	66,027	565,045	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Jan 30 '26	Sale	4.13	5,686	23,483	559,359	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Feb 02 '26	Sale	4.04	3,800	15,352	555,559	Feb 02 05:10 PM
Ugwumba Chidozie	10% Owner	Jan 28 '26	Sale	4.91	8,717	42,800	580,329	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 26 '26	Sale	5.02	6,418	32,218	593,185	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 27 '26	Sale	5.08	4,139	21,026	589,046	Jan 28 05:01 PM
Ugwumba Chidozie	10% Owner	Jan 22 '26	Sale	5.32	12,665	67,378	605,159	Jan 23 05:33 PM
Ugwumba Chidozie	10% Owner	Jan 23 '26	Sale	5.27	5,556	29,280	599,603	Jan 23 05:33 PM
Ugwumba Chidozie	10% Owner	Jan 21 '26	Sale	5.05	12,119	61,201	617,824	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 20 '26	Sale	4.80	12,432	59,674	629,943	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 16 '26	Sale	5.13	7,923	40,645	642,375	Jan 21 06:13 PM
Ugwumba Chidozie	10% Owner	Jan 13 '26	Sale	4.89	26,105	127,653	682,482	Jan 16 11:16 AM
Ugwumba Chidozie	10% Owner	Jan 14 '26	Sale	5.12	19,621	100,460	662,861	Jan 16 11:16 AM
Ugwumba Chidozie	10% Owner	Jan 15 '26	Sale	5.10	12,563	64,071	650,298	Jan 16 11:16 AM
MATLIN DAVID J	Director	Jan 13 '26	Buy	6.50	33,333	216,664	477,824	Jan 13 02:48 PM
Ugwumba Chidozie	10% Owner	Jan 12 '26	Sale	5.50	32,705	179,878	708,587	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 09 '26	Sale	6.27	9,075	56,900	741,292	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 08 '26	Sale	6.09	3,195	19,458	750,367	Jan 12 04:38 PM
Ugwumba Chidozie	10% Owner	Jan 05 '26	Sale	5.87	5,869	34,451	760,611	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Jan 07 '26	Sale	6.29	3,938	24,770	753,562	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Jan 06 '26	Sale	6.04	3,111	18,790	757,500	Jan 07 05:28 PM
Ugwumba Chidozie	10% Owner	Dec 31 '25	Sale	5.81	13,095	76,082	770,495	Jan 02 05:25 PM
Ugwumba Chidozie	10% Owner	Jan 02 '26	Sale	5.73	4,015	23,006	766,480	Jan 02 05:25 PM
Ugwumba Chidozie	10% Owner	Dec 29 '25	Sale	5.95	8,096	48,171	787,728	Dec 31 12:10 PM
Ugwumba Chidozie	10% Owner	Dec 30 '25	Sale	6.03	4,138	24,952	783,590	Dec 31 12:10 PM
Ugwumba Chidozie	10% Owner	Dec 23 '25	Sale	6.27	6,831	42,830	800,664	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 26 '25	Sale	6.32	3,350	21,172	795,824	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 24 '25	Sale	6.27	1,490	9,342	799,174	Dec 30 09:03 PM
Ugwumba Chidozie	10% Owner	Dec 19 '25	Sale	6.45	5,582	36,004	387,568	Dec 23 04:37 PM
Ugwumba Chidozie	10% Owner	Dec 22 '25	Sale	6.54	4,367	28,560	383,201	Dec 23 04:37 PM
Ugwumba Chidozie	10% Owner	Dec 04 '25	Sale	6.73	72,748	489,594	521,620	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 03 '25	Sale	7.86	56,577	444,695	594,368	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 05 '25	Sale	5.94	37,235	221,176	484,385	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 08 '25	Sale	5.70	21,463	122,339	462,922	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 09 '25	Sale	5.95	15,031	89,434	447,891	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 11 '25	Sale	6.81	10,907	74,277	427,063	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 15 '25	Sale	6.49	10,580	68,664	408,880	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 10 '25	Sale	6.42	9,921	63,693	437,970	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 12 '25	Sale	6.79	7,603	51,624	419,460	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 16 '25	Sale	6.31	7,030	44,359	401,850	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 18 '25	Sale	6.33	5,816	36,815	393,150	Dec 18 05:08 PM
Ugwumba Chidozie	10% Owner	Dec 17 '25	Sale	6.61	2,884	19,063	398,966	Dec 18 05:08 PM
Symbiosis II LLC	Prior Board Member	Dec 03 '25	Proposed Sale	7.46	506,384	3,775,481		Dec 05 04:14 PM
General Resonance LLC	10% Owner	Aug 21 '25	Sale	5.34	3,401	18,161	704,591	Aug 21 08:44 PM
General Resonance LLC	10% Owner	Jun 04 '25	Sale	4.04	600	2,424	707,992	Jun 04 03:23 PM
General Resonance LLC	10% Owner	Jun 02 '25	Sale	4.12	600	2,473	708,592	Jun 02 02:39 PM
General Resonance LLC	10% Owner	May 30 '25	Sale	2.80	410	1,148	709,192	May 30 02:40 PM
General Resonance LLC	10% Owner	May 29 '25	Sale	2.73	410	1,119	709,602	May 29 03:58 PM
General Resonance LLC	10% Owner	May 28 '25	Sale	2.60	420	1,090	710,012	May 28 02:05 PM
General Resonance LLC	10% Owner	May 27 '25	Sale	2.45	420	1,029	710,432	May 27 03:29 PM
General Resonance LLC	10% Owner	Mar 19 '25	Sale	4.40	1,400	6,160	710,852	Mar 19 06:47 PM
General Resonance LLC	10% Owner	Mar 18 '25	Sale	4.45	1,333	5,932	712,252	Mar 19 06:47 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLNN

Clene Inc

Upgrade your FINVIZ experience